Search: id:"swepub:oai:prod.swepub.kib.ki.se:138066223" >
The efficacy of ter...
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
-
Freedman, MS (author)
-
Wolinsky, JS (author)
-
Comi, G (author)
-
show more...
-
Kappos, L (author)
-
- Olsson, TP (author)
- Karolinska Institutet
-
Miller, AE (author)
-
Thangavelu, K (author)
-
Benamor, M (author)
-
Truffinet, P (author)
-
O'Connor, PW (author)
-
show less...
-
(creator_code:org_t)
- 2017-03-17
- 2018
- English.
-
In: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 24:4, s. 535-539
- Related links:
-
https://journals.sag...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Freedman, MS
-
Wolinsky, JS
-
Comi, G
-
Kappos, L
-
Olsson, TP
-
Miller, AE
-
show more...
-
Thangavelu, K
-
Benamor, M
-
Truffinet, P
-
O'Connor, PW
-
show less...
- Articles in the publication
-
Multiple scleros ...
- By the university
-
Karolinska Institutet